# A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

> **NCT01178073** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 610 (actual)

## Conditions studied

- Hypertension, Pulmonary

## Interventions

- **DRUG:** ambrisentan
- **DRUG:** tadalafil

## Key facts

- **NCT ID:** NCT01178073
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-01
- **Primary completion:** 2014-07-31
- **Final completion:** 2014-07-31
- **Target enrollment:** 610 (ACTUAL)
- **Last updated:** 2017-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01178073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01178073, "A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT01178073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*